{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:16:32Z","timestamp":1790727392491,"version":"4.1.0"},"reference-count":42,"publisher":"American Society of Hematology","issue":"6","license":[{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,26]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The curative potential of allogeneic hematopoietic transplantation (allo-HCT) in patients with acute lymphoblastic leukemia (ALL) is hampered by relapse. Inotuzumab ozogamicin (INO) is an anti-CD22 monoclonal antibody bound to calicheamicin, which has significant activity against ALL. We hypothesized that low-dose INO would be safe and feasible after allo-HCT. Therefore, we conducted a phase 1 study to determine the dose and safety in this setting. Patients were eligible if they were aged 16 to 75 years, had undergone allo-HCT for CD22+ ALL, were in complete remission (CR) after allo-HCT, had high risk of recurrence, were between day 40 and 100 after allo-HCT with adequate graft function, and did not have a history of sinusoidal obstruction syndrome (SOS). The objectives of this trial were to define INO maximum tolerated dose (MTD), to determine post\u2013allo-HCT INO safety, and to measure 1-year progression-free survival (PFS). The trial design followed a \u201c3+3\u201d model. The treatment consisted of INO given on day 1 of 28-day cycles. Dose levels were 0.3\u00a0mg\/m2, 0.4\u00a0mg\/m2, 0.5\u00a0mg\/m2, and 0.6\u00a0mg\/m2. Median age was 44 years (range, 17-66 years; n\u00a0= 18). Disease status at transplantation was first CR (n\u00a0= 14) or second CR or beyond (n\u00a0= 4). Preparative regimen was of reduced intensity in 72% of patients who received transplantation. Most common toxicity was thrombocytopenia. There were no instances of SOS; the MTD was 0.6\u00a0mg\/m2. One-year nonrelapse mortality was 5.6%. With a median follow-up of 18.1\u00a0months (range, 8.6-59\u00a0months) 1-year post\u2013allo-HCT PFS and overall survival is 89% and 94%, respectively. Low-dose INO has a favorable safety profile and was associated with high rates of 1-year PFS. This trial was registered at www.clinicaltrials.gov as #NCT03104491.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011514","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T18:47:54Z","timestamp":1704307674000},"page":"1384-1391","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":31,"title":["A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1980-9999","authenticated-orcid":false,"given":"Leland L.","family":"Metheny","sequence":"first","affiliation":[{"name":"1Hematology and Cell Therapy Division, Seidman Cancer Center, University Hospitals, Cleveland, OH"},{"name":"2Case Comprehensive Cancer Center, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Sobecks","sequence":"additional","affiliation":[{"name":"2Case Comprehensive Cancer Center, Cleveland, OH"},{"name":"3Blood and Marrow Transplant, Cleveland Clinic Foundation, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Cho","sequence":"additional","affiliation":[{"name":"4Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"5Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2334-5218","authenticated-orcid":false,"given":"Pingfu","family":"Fu","sequence":"additional","affiliation":[{"name":"6Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seunghee","family":"Margevicius","sequence":"additional","affiliation":[{"name":"6Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiasheng","family":"Wang","sequence":"additional","affiliation":[{"name":"1Hematology and Cell Therapy Division, Seidman Cancer Center, University Hospitals, Cleveland, OH"},{"name":"2Case Comprehensive Cancer Center, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Ciarrone","sequence":"additional","affiliation":[{"name":"1Hematology and Cell Therapy Division, Seidman Cancer Center, University Hospitals, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelby","family":"Kopp","sequence":"additional","affiliation":[{"name":"1Hematology and Cell Therapy Division, Seidman Cancer Center, University Hospitals, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin D.","family":"Convents","sequence":"additional","affiliation":[{"name":"1Hematology and Cell Therapy Division, Seidman Cancer Center, University Hospitals, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7082-891X","authenticated-orcid":false,"given":"Navneet","family":"Majhail","sequence":"additional","affiliation":[{"name":"2Case Comprehensive Cancer Center, Cleveland, OH"},{"name":"3Blood and Marrow Transplant, Cleveland Clinic Foundation, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1436-0464","authenticated-orcid":false,"given":"Paolo F.","family":"Caimi","sequence":"additional","affiliation":[{"name":"2Case Comprehensive Cancer Center, Cleveland, OH"},{"name":"3Blood and Marrow Transplant, Cleveland Clinic Foundation, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folashade","family":"Otegbeye","sequence":"additional","affiliation":[{"name":"7Clinical Research Division, Fred Hutchison Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda W.","family":"Cooper","sequence":"additional","affiliation":[{"name":"1Hematology and Cell Therapy Division, Seidman Cancer Center, University Hospitals, Cleveland, OH"},{"name":"2Case Comprehensive Cancer Center, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Gallogly","sequence":"additional","affiliation":[{"name":"1Hematology and Cell Therapy Division, Seidman Cancer Center, University Hospitals, Cleveland, OH"},{"name":"2Case Comprehensive Cancer Center, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Malek","sequence":"additional","affiliation":[{"name":"1Hematology and Cell Therapy Division, Seidman Cancer Center, University Hospitals, Cleveland, OH"},{"name":"2Case Comprehensive Cancer Center, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2407-0973","authenticated-orcid":false,"given":"Benjamin","family":"Tomlinson","sequence":"additional","affiliation":[{"name":"1Hematology and Cell Therapy Division, Seidman Cancer Center, University Hospitals, Cleveland, OH"},{"name":"2Case Comprehensive Cancer Center, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3422-1309","authenticated-orcid":false,"given":"Aaron T.","family":"Gerds","sequence":"additional","affiliation":[{"name":"2Case Comprehensive Cancer Center, Cleveland, OH"},{"name":"3Blood and Marrow Transplant, Cleveland Clinic Foundation, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty","family":"Hamilton","sequence":"additional","affiliation":[{"name":"2Case Comprehensive Cancer Center, Cleveland, OH"},{"name":"3Blood and Marrow Transplant, Cleveland Clinic Foundation, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1944-5053","authenticated-orcid":false,"given":"Sergio","family":"Giralt","sequence":"additional","affiliation":[{"name":"4Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"5Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[{"name":"4Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"5Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8568-4522","authenticated-orcid":false,"given":"Marcos","family":"de Lima","sequence":"additional","affiliation":[{"name":"8Hematology, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,3,13]]},"reference":[{"issue":"16","key":"2024032513103506500_bib1","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1200\/JCO.2010.33.7212","article-title":"Long-term survival and late deaths after allogeneic hematopoietic cell transplantation","volume":"29","author":"Wingard","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024032513103506500_bib2","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/bloodadvances.2021004916","article-title":"Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia","volume":"6","author":"Wieduwilt","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"2024032513103506500_bib3","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/bmt.2012.195","article-title":"Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia","volume":"48","author":"Poon","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2024032513103506500_bib4","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.bbmt.2013.04.014","article-title":"Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation","volume":"19","author":"Poon","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2024032513103506500_bib5","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/leu.2011.351","article-title":"Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT","volume":"26","author":"Spyridonidis","year":"2012","journal-title":"Leukemia"},{"issue":"1","key":"2024032513103506500_bib6","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13045-019-0790-x","article-title":"Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the Acute Leukemia Working Party of the EBMT","volume":"12","author":"Pavlu","year":"2019","journal-title":"J\u00a0Hematol Oncol"},{"issue":"11","key":"2024032513103506500_bib7","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1182\/blood.V92.11.4072","article-title":"Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia","volume":"92","author":"Knechtli","year":"1998","journal-title":"Blood"},{"issue":"6","key":"2024032513103506500_bib8","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1182\/blood.V98.6.1982","article-title":"The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia","volume":"98","author":"Uzunel","year":"2001","journal-title":"Blood"},{"issue":"8","key":"2024032513103506500_bib9","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/sj.bmt.1704241","article-title":"Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group","volume":"32","author":"Krejci","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2024032513103506500_bib10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/pbc.20794","article-title":"Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia","volume":"48","author":"Sramkova","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"8719","key":"2024032513103506500_bib11","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/0140-6736(90)92414-D","article-title":"Prediction of clinical relapse after bone-marrow transplantation by PCR for Philadelphia-positive acute lymphoblastic leukaemia","volume":"336","author":"Miyamura","year":"1990","journal-title":"Lancet"},{"issue":"6","key":"2024032513103506500_bib12","first-page":"2415","article-title":"Impact of post-transplant imatinib administration on Philadelphia chromosome-positive acute lymphoblastic leukaemia","volume":"30","author":"Nishiwaki","year":"2010","journal-title":"Anticancer Res"},{"issue":"4","key":"2024032513103506500_bib13","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","article-title":"In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation\/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII\/ECOG E2993)","volume":"111","author":"Goldstone","year":"2008","journal-title":"Blood"},{"issue":"7","key":"2024032513103506500_bib14","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/bmt.2009.324","article-title":"Long-term outcomes in adult patients below the age of 55 years with acute lymphoblastic leukemia treated with chemotherapy or allogeneic BM transplant in first CR","volume":"45","author":"Kohli","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"16","key":"2024032513103506500_bib15","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1182\/blood-2014-09-599894","article-title":"Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia","volume":"125","author":"Dhedin","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2024032513103506500_bib16","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/leu.2008.164","article-title":"Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a 'donor' versus 'no donor' comparison","volume":"23","author":"Mohty","year":"2009","journal-title":"Leukemia"},{"issue":"18","key":"2024032513103506500_bib17","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1002\/cncr.26033","article-title":"Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: real-world population-based data from the Swedish Acute Leukemia Registry 1997-2006","volume":"117","author":"Juliusson","year":"2011","journal-title":"Cancer"},{"issue":"2","key":"2024032513103506500_bib18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/bmt.2008.296","article-title":"Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival","volume":"43","author":"Burke","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2024032513103506500_bib19","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1182\/blood-2004-05-1746","article-title":"Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"106","author":"Wassmann","year":"2005","journal-title":"Blood"},{"issue":"7","key":"2024032513103506500_bib20","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2006-04-019836","article-title":"Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia","volume":"109","author":"Carpenter","year":"2007","journal-title":"Blood"},{"issue":"12","key":"2024032513103506500_bib21","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.bbmt.2004.09.004","article-title":"Re: imatinib mesylate administration in the first 100\u00a0days after stem cell transplantation","volume":"10","author":"Anderlini","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"issue":"15","key":"2024032513103506500_bib22","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/cncr.28136","article-title":"Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia","volume":"119","author":"Kantarjian","year":"2013","journal-title":"Cancer"},{"issue":"2","key":"2024032513103506500_bib23","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/pbc.24721","article-title":"Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia","volume":"61","author":"Rytting","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"2024032513103506500_bib24","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2024032513103506500_bib25","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/j.bbmt.2019.04.020","article-title":"Outcomes of allogeneic stem cell transplantation after inotuzumab ozogamicin treatment for relapsed or refractory acute lymphoblastic leukemia","volume":"25","author":"Marks","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2024032513103506500_bib26","first-page":"161","article-title":"Management of acute lymphoblastic leukemia in older adults","volume":"20","author":"Jammal","year":"2022","journal-title":"Clin Adv Hematol Oncol"},{"issue":"12","key":"2024032513103506500_bib27","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/cncr.33469","article-title":"Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed\/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"127","author":"Jabbour","year":"2021","journal-title":"Cancer"},{"issue":"3","key":"2024032513103506500_bib28","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2307\/2531693","article-title":"Design and analysis of phase I clinical trials","volume":"45","author":"Storer","year":"1989","journal-title":"Biometrics"},{"issue":"282","key":"2024032513103506500_bib29","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J\u00a0Am Stat Assoc"},{"issue":"3","key":"2024032513103506500_bib30","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A\u00a0class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"key":"2024032513103506500_bib31","unstructured":"National Comprehensive Cancer Network\n          . Acute Lymphoblastic Leukemia (Version 3.2023). Accessed 11 October 2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/all.pdf."},{"issue":"8","key":"2024032513103506500_bib32","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","article-title":"Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study","volume":"4","author":"Kantarjian","year":"2017","journal-title":"Lancet Haematol"},{"issue":"14","key":"2024032513103506500_bib33","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"issue":"suppl 1","key":"2024032513103506500_bib34","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood-2022-170667","article-title":"A\u00a0phase II study of inotuzumab ozogamicin for the treatment of measurable residual disease-positive B-cell acute lymphoblastic leukemia","volume":"140","author":"Senapati","year":"2022","journal-title":"Blood"},{"issue":"9","key":"2024032513103506500_bib35","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.6004\/jnccn.2021.0042","article-title":"Acute lymphoblastic leukemia, version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Brown","year":"2021","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"issue":"3","key":"2024032513103506500_bib36","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/bmt.2008.135","article-title":"Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population","volume":"42","author":"Levine","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2024032513103506500_bib37","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41409-021-01515-3","article-title":"Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia","volume":"57","author":"Schmid","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"2024032513103506500_bib38","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.3390\/cancers13112699","article-title":"Repetitively administered low-dose donor lymphocyte infusion for prevention of relapse after allogeneic stem cell transplantation in patients with high-risk acute leukemia","volume":"13","author":"Tsirigotis","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"2024032513103506500_bib39","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/sj.bmt.1705024","article-title":"Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a prospective study","volume":"36","author":"Choi","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2024032513103506500_bib40","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2024032513103506500_bib41","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1038\/s41409-020-0878-5","article-title":"Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia &gt;45 years undergoing allogeneic stem cell transplantation-a retrospective study by the Acute Leukemia Working Party of EBMT","volume":"55","author":"Peric","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2024032513103506500_bib42","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1007\/s12032-014-0938-z","article-title":"Clinical significance of minimal residual disease in young adults with standard-risk\/Ph-negative precursor B-acute lymphoblastic leukemia: results of prospective study","volume":"31","author":"Salah-Eldin","year":"2014","journal-title":"Med Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/6\/1384\/2218935\/blooda_adv-2023-011514-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/6\/1384\/2218935\/blooda_adv-2023-011514-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T13:11:56Z","timestamp":1711372316000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/6\/1384\/506928\/A-multicenter-study-of-posttransplantation-low"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,13]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,3,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011514","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,13]]}}}